Table 1 Demographic and clinical characteristics of patient cohorts profiled for expression of NALPs and other inflammasome components and targets
Demographic or clinical parameter (N = 45) | Average ± SD or percentage |
|---|---|
Clinical & Demographic Data | |
BMI | 47.4 ± 10.8 |
Age | 42.7 ± 11.9 |
Gender (Females) | 62.2% |
Triglyceride (mg/dL) | 158.3 ± 96.7 |
AST (U/L) | 27.7 ± 18.8 |
ALT (U/L) | 36.7 ± 29.3 |
Glucose (mg/dL) | 106.4 ± 32.2 |
Diabetes (Presence) | 57.7% |
Liver Histological Data | |
Non-NASH NAFLD | 55.5% |
NASH (Presence) | 44.4% |
Ballooning Degeneration (Presence) | 28.8% |
Mallory-Denk Bodies (Presence) | 11.1% |
Portal Inflammation (Presence) | 66.6% |
Advanced Lobular Inflammation (Score ≥ 3) | 28.8% |
Pericellular Fibrosis (Presence) | 44.4% |
Portal Fibrosis (Presence) | 75.5% |
Advanced Fibrosis (Score ≥ 3) | 31.1% |
Focal Necrosis (Presence) | 31.1% |